NO321729B1 - Forbedret system for administrasjon av medikamenter til slim-overflater - Google Patents

Forbedret system for administrasjon av medikamenter til slim-overflater Download PDF

Info

Publication number: NO321729B1
Authority: NO; Norway
Prior art keywords: mixture; accordance; pectin; compound; therapeutic compound
Prior art date: 1997-04-18

Application number

NO19995021A

Other languages

English (en)

Norwegian (no)

Other versions

NO995021L (no

NO995021D0 (no

Inventor

Lisbeth Illum

Peter James Watts

Original Assignee

West Pharmaceutical Service Dr

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-18

Filing date

1999-10-15

Publication date

2006-06-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10811025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO321729(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-10-15 Application filed by West Pharmaceutical Service Dr filed Critical West Pharmaceutical Service Dr

1999-10-15 Publication of NO995021L publication Critical patent/NO995021L/no

1999-10-15 Publication of NO995021D0 publication Critical patent/NO995021D0/no

2006-06-26 Publication of NO321729B1 publication Critical patent/NO321729B1/no

Links

239000003814 drug Substances 0.000 title claims abstract description 55
229940079593 drug Drugs 0.000 title claims description 50
239000000203 mixture Substances 0.000 claims abstract description 138
229920001277 pectin Polymers 0.000 claims abstract description 120
239000001814 pectin Substances 0.000 claims abstract description 116
235000010987 pectin Nutrition 0.000 claims abstract description 116
239000007788 liquid Substances 0.000 claims abstract description 24
229910021645 metal ion Inorganic materials 0.000 claims abstract description 20
238000005886 esterification reaction Methods 0.000 claims abstract description 9
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
230000032050 esterification Effects 0.000 claims abstract description 7
150000001875 compounds Chemical class 0.000 claims description 75
239000000499 gel Substances 0.000 claims description 59
230000001225 therapeutic effect Effects 0.000 claims description 50
210000001215 vagina Anatomy 0.000 claims description 17
210000003097 mucus Anatomy 0.000 claims description 15
210000001331 nose Anatomy 0.000 claims description 14
239000008365 aqueous carrier Substances 0.000 claims description 12
210000000664 rectum Anatomy 0.000 claims description 12
238000011282 treatment Methods 0.000 claims description 11
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 10
238000009472 formulation Methods 0.000 claims description 10
229960002715 nicotine Drugs 0.000 claims description 10
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 10
229960005486 vaccine Drugs 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 8
229960003592 fexofenadine Drugs 0.000 claims description 7
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 6
210000003928 nasal cavity Anatomy 0.000 claims description 6
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 6
239000007921 spray Substances 0.000 claims description 6
239000008252 pharmaceutical gel Substances 0.000 claims description 5
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 4
229960004046 apomorphine Drugs 0.000 claims description 4
239000000850 decongestant Substances 0.000 claims description 4
-1 oxymetazaline Chemical compound 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 3
230000003509 anti-fertility effect Effects 0.000 claims description 3
230000000840 anti-viral effect Effects 0.000 claims description 3
239000002552 dosage form Substances 0.000 claims description 3
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 3
229960002428 fentanyl Drugs 0.000 claims description 3
229960003712 propranolol Drugs 0.000 claims description 3
CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 claims description 2
229930183010 Amphotericin Natural products 0.000 claims description 2
QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims description 2
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 2
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 2
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 2
201000005702 Pertussis Diseases 0.000 claims description 2
HEUMNKZPHGRBKR-UHFFFAOYSA-N [Na].[Cr] Chemical compound [Na].[Cr] HEUMNKZPHGRBKR-UHFFFAOYSA-N 0.000 claims description 2
229960004150 aciclovir Drugs 0.000 claims description 2
229940009444 amphotericin Drugs 0.000 claims description 2
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 2
230000003266 anti-allergic effect Effects 0.000 claims description 2
230000000844 anti-bacterial effect Effects 0.000 claims description 2
239000000739 antihistaminic agent Substances 0.000 claims description 2
229960001169 brivudine Drugs 0.000 claims description 2
229960004436 budesonide Drugs 0.000 claims description 2
229960000525 diphenhydramine hydrochloride Drugs 0.000 claims description 2
229960005097 diphtheria vaccines Drugs 0.000 claims description 2
229960002714 fluticasone Drugs 0.000 claims description 2
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 2
239000000417 fungicide Substances 0.000 claims description 2
229940047135 glycate Drugs 0.000 claims description 2
ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 claims description 2
229940124512 hyoscine hydrobromide Drugs 0.000 claims description 2
229960003971 influenza vaccine Drugs 0.000 claims description 2
229940047124 interferons Drugs 0.000 claims description 2
229960004194 lidocaine Drugs 0.000 claims description 2
229940041323 measles vaccine Drugs 0.000 claims description 2
UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 claims description 2
229960005254 naratriptan Drugs 0.000 claims description 2
229960000988 nystatin Drugs 0.000 claims description 2
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 2
239000003016 pheromone Substances 0.000 claims description 2
230000000069 prophylactic effect Effects 0.000 claims description 2
LACQPOBCQQPVIT-SEYKEWMNSA-N scopolamine hydrobromide trihydrate Chemical compound O.O.O.Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 LACQPOBCQQPVIT-SEYKEWMNSA-N 0.000 claims description 2
150000003431 steroids Chemical class 0.000 claims description 2
229960002555 zidovudine Drugs 0.000 claims description 2
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 2
102000053602 DNA Human genes 0.000 claims 1
108020004414 DNA Proteins 0.000 claims 1
241000725643 Respiratory syncytial virus Species 0.000 claims 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
230000001387 anti-histamine Effects 0.000 claims 1
230000000855 fungicidal effect Effects 0.000 claims 1
230000001050 lubricating effect Effects 0.000 claims 1
239000000934 spermatocidal agent Substances 0.000 claims 1
108700026220 vif Genes Proteins 0.000 claims 1
229940124597 therapeutic agent Drugs 0.000 abstract description 2
239000000243 solution Substances 0.000 description 27
239000000463 material Substances 0.000 description 17
238000000034 method Methods 0.000 description 13
210000004400 mucous membrane Anatomy 0.000 description 13
241001494479 Pecora Species 0.000 description 10
238000010521 absorption reaction Methods 0.000 description 10
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 9
229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 9
108010068072 salmon calcitonin Proteins 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
150000002500 ions Chemical class 0.000 description 8
230000009885 systemic effect Effects 0.000 description 8
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
229960005069 calcium Drugs 0.000 description 7
239000011575 calcium Substances 0.000 description 7
229910052791 calcium Inorganic materials 0.000 description 7
239000008151 electrolyte solution Substances 0.000 description 7
238000001879 gelation Methods 0.000 description 7
230000008901 benefit Effects 0.000 description 6
230000028327 secretion Effects 0.000 description 6
239000007787 solid Substances 0.000 description 6
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 5
239000000227 bioadhesive Substances 0.000 description 5
229910001424 calcium ion Inorganic materials 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000012530 fluid Substances 0.000 description 5
150000004676 glycans Polymers 0.000 description 5
230000008569 process Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
230000008859 change Effects 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
229920001661 Chitosan Polymers 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000002253 acid Substances 0.000 description 3
IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical group O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 3
239000013011 aqueous formulation Substances 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
229960000265 cromoglicic acid Drugs 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
210000002919 epithelial cell Anatomy 0.000 description 3
210000001508 eye Anatomy 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
210000004731 jugular vein Anatomy 0.000 description 3
210000004877 mucosa Anatomy 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
239000000843 powder Substances 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000001839 systemic circulation Effects 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
QLDPCHZQQIASHX-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.CN1CCCC1C1=CC=CN=C1 QLDPCHZQQIASHX-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
241000792859 Enema Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229920002230 Pectic acid Polymers 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
230000001886 ciliary effect Effects 0.000 description 2
230000004087 circulation Effects 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
229940124581 decongestants Drugs 0.000 description 2
239000003792 electrolyte Substances 0.000 description 2
239000007920 enema Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000017 hydrogel Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
210000003563 lymphoid tissue Anatomy 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
230000003232 mucoadhesive effect Effects 0.000 description 2
230000002572 peristaltic effect Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
239000001103 potassium chloride Substances 0.000 description 2
235000011164 potassium chloride Nutrition 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
230000001150 spermicidal effect Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
238000001890 transfection Methods 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
235000002961 Aloe barbadensis Nutrition 0.000 description 1
244000186892 Aloe vera Species 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
208000004926 Bacterial Vaginosis Diseases 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
241000207199 Citrus Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
229940021995 DNA vaccine Drugs 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
208000001860 Eye Infections Diseases 0.000 description 1
RRJFVPUCXDGFJB-UHFFFAOYSA-N Fexofenadine hydrochloride Chemical compound Cl.C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RRJFVPUCXDGFJB-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000715 Mucilage Polymers 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
208000030880 Nose disease Diseases 0.000 description 1
108010016076 Octreotide Proteins 0.000 description 1
206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
206010046914 Vaginal infection Diseases 0.000 description 1
208000037009 Vaginitis bacterial Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
229940124532 absorption promoter Drugs 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
235000011399 aloe vera Nutrition 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
239000004227 calcium gluconate Substances 0.000 description 1
229960004494 calcium gluconate Drugs 0.000 description 1
235000013927 calcium gluconate Nutrition 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000004081 cilia Anatomy 0.000 description 1
235000020971 citrus fruits Nutrition 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
239000012612 commercial material Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
RMGVZKRVHHSUIM-UHFFFAOYSA-L dithionate(2-) Chemical compound [O-]S(=O)(=O)S([O-])(=O)=O RMGVZKRVHHSUIM-UHFFFAOYSA-L 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
208000011323 eye infectious disease Diseases 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
229960000354 fexofenadine hydrochloride Drugs 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000005755 formation reaction Methods 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000001057 ionotropic effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000009245 menopause Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
238000006198 methoxylation reaction Methods 0.000 description 1
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
230000003020 moisturizing effect Effects 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
210000004083 nasolacrimal duct Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940066827 pertussis vaccine Drugs 0.000 description 1
239000008014 pharmaceutical binder Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000010318 polygalacturonic acid Substances 0.000 description 1
150000004804 polysaccharides Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
210000001578 tight junction Anatomy 0.000 description 1
230000032258 transport Effects 0.000 description 1
229910021642 ultra pure water Inorganic materials 0.000 description 1
239000012498 ultrapure water Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019158 vitamin B6 Nutrition 0.000 description 1
239000011726 vitamin B6 Substances 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
229940011671 vitamin b6 Drugs 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
238000005303 weighing Methods 0.000 description 1
235000016804 zinc Nutrition 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Dispersion Chemistry (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Otolaryngology (AREA)
Oncology (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Inorganic Chemistry (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Molecular Biology (AREA)
Psychology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO19995021A 1997-04-18 1999-10-15 Forbedret system for administrasjon av medikamenter til slim-overflater NO321729B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9707934.7A GB9707934D0 (en)	1997-04-18	1997-04-18	Improved delivery of drugs to mucosal surfaces
PCT/GB1998/001147 WO1998047535A1 (en)	1997-04-18	1998-04-20	Improved delivery of drugs to mucosal surfaces

Publications (3)

Publication Number	Publication Date
NO995021L NO995021L (no)	1999-10-15
NO995021D0 NO995021D0 (no)	1999-10-15
NO321729B1 true NO321729B1 (no)	2006-06-26

Family

ID=10811025

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19995021A NO321729B1 (no)	1997-04-18	1999-10-15	Forbedret system for administrasjon av medikamenter til slim-overflater

Country Status (15)

Country	Link
US (5)	US6432440B1 (de)
EP (1)	EP0975367B1 (de)
JP (3)	JP2001524094A (de)
AT (1)	ATE262925T1 (de)
CA (1)	CA2282506C (de)
DE (2)	DE69822805T2 (de)
DK (1)	DK0975367T3 (de)
ES (1)	ES2221706T3 (de)
FR (1)	FR11C0006I1 (de)
GB (2)	GB9707934D0 (de)
NO (1)	NO321729B1 (de)
NZ (1)	NZ337289A (de)
PT (1)	PT975367E (de)
WO (1)	WO1998047535A1 (de)
ZA (1)	ZA983262B (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9707934D0 (en) *	1997-04-18	1997-06-04	Danbiosyst Uk	Improved delivery of drugs to mucosal surfaces
CN1159012C (zh) *	1997-08-26	2004-07-28	阿旺蒂斯制药公司	用于组合哌啶子基烷醇-减充血剂的药物组合物
US20040265377A1 (en) *	1997-10-27	2004-12-30	Harry Seager	Solid dispersing vaccine composition for oral delivery
WO1999027905A1 (en) *	1997-12-02	1999-06-10	West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited	Compositions for nasal administration
US7022683B1 (en)	1998-05-13	2006-04-04	Carrington Laboratories, Inc.	Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
GB9822170D0 (en) *	1998-10-13	1998-12-02	Danbioyst Uk Ltd	Novel formulations of fexofenadine
GB0000001D0 (en) *	2000-01-05	2000-02-23	Du Pont Uk	Pharmaceutical compositions and their preparation
JP4898073B2 (ja)	2000-07-31	2012-03-14	ニュコメデダンマルクアンパーツセルスカブ	鼻内投与用フェンタニル組成物
US6777000B2 (en) *	2001-02-28	2004-08-17	Carrington Laboratories, Inc.	In-situ gel formation of pectin
US7494669B2 (en)	2001-02-28	2009-02-24	Carrington Laboratories, Inc.	Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
DE10141650C1 (de)	2001-08-24	2002-11-28	Lohmann Therapie Syst Lts	Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
EP1476135A1 (de)	2002-02-22	2004-11-17	Pharmacia Corporation	Ophthalmische formulierung mit gummi-system
US7666876B2 (en) *	2002-03-19	2010-02-23	Vernalis (R&D) Limited	Buprenorphine formulations for intranasal delivery
WO2004003145A2 (en) *	2002-06-28	2004-01-08	Nastech Pharmaceutical Company Inc.	Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
US7186692B2 (en) *	2002-12-17	2007-03-06	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7229966B2 (en) *	2002-12-17	2007-06-12	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) *	2002-12-17	2007-01-23	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
EA008829B1 (ru) *	2002-12-17	2007-08-31	Нэстек Фармасьютикал Кампани Инк.	Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения
GB0300531D0 (en)	2003-01-10	2003-02-12	West Pharm Serv Drug Res Ltd	Pharmaceutical compositions
SE0302947D0 (sv) *	2003-01-24	2003-11-07	Magle Ab	A composition material for transmucosal delivery
TR201907898T4 (tr)	2003-01-31	2019-06-21	Dsm Ip Assets Bv	Karotenoidler içeren yeni bileşimler.
AU2004235744A1 (en) *	2003-05-01	2004-11-18	Archimedes Development Limited	Nasal administration of the LH-RH analog leuprolide
GB0315632D0 (en) *	2003-07-04	2003-08-13	West Pharm Serv Drug Res Ltd	Pharmaceutical formulations
ATE319426T1 (de)	2003-11-11	2006-03-15	Mattern Udo	Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
US8784869B2 (en)	2003-11-11	2014-07-22	Mattern Pharma Ag	Controlled release delivery system for nasal applications and methods of treatment
US20050113730A1 (en) *	2003-11-24	2005-05-26	Sca Hygiene Products Ab	Absorbent Article Containing A Skin Care Product
US20050129679A1 (en)	2003-12-15	2005-06-16	Nastech Pharmaceutical Company Inc.	Method for opening tight junctions
US20070213270A1 (en) *	2004-06-16	2007-09-13	Costantino Henry R	Peptide yy formulations having increased stability and resistance to microbial agents
WO2006039400A2 (en)	2004-09-29	2006-04-13	Mount Sinai School Of Medicine Of New York University	Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
US7619008B2 (en) *	2004-11-12	2009-11-17	Kimberly-Clark Worldwide, Inc.	Xylitol for treatment of vaginal infections
US20060140820A1 (en)	2004-12-28	2006-06-29	Udo Mattern	Use of a container of an inorganic additive containing plastic material
US20060217443A1 (en) *	2005-03-28	2006-09-28	Kimberly-Clark Worldwide, Inc.	Method for preventing and/or treating vaginal and vulval infections
US7786176B2 (en)	2005-07-29	2010-08-31	Kimberly-Clark Worldwide, Inc.	Vaginal treatment composition containing xylitol
US20070232537A1 (en) *	2005-12-19	2007-10-04	Nastech Pharmaceutical Company Inc.	Intranasal pyy formulations with improved transmucosal pharmacokinetics
CN102488652B (zh)	2006-03-16	2014-06-18	特瑞斯制药股份有限公司	含有药物-离子交换树脂复合物的经修饰释放的制剂
AU2007285472B2 (en) *	2006-03-30	2013-10-24	Engene, Inc.	Non-viral compositions and methods for transfecting gut cells in vivo
WO2008040488A1 (en)	2006-10-04	2008-04-10	M & P Patent Aktiengesellschaft	Controlled release delivery system for nasal application of neurotransmitters
WO2008091592A1 (en)	2007-01-22	2008-07-31	Targacept, Inc.	Intranasal, buccal, and sublingual administration of metanicotine analogs
BRPI0807880A2 (pt) *	2007-03-02	2014-06-17	Combe Internat Ltd	Composição anestésica em spray.
US20120058198A1 (en) *	2009-03-26	2012-03-08	Pulmatrix, Inc.	Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
NZ624922A (en)	2009-10-01	2016-05-27	Adare Pharmaceuticals Inc	Orally administered corticosteroid compositions
CZ302789B6 (cs)	2009-11-25	2011-11-09	Zentiva, K. S.	Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
GB2482536B (en)	2010-08-05	2013-07-24	Hera Pharmaceuticals Inc	Expression of antibody or a fragment thereof in lactobacillus
GB2482535A (en) *	2010-08-05	2012-02-08	Hera Pharmaceuticals Inc	Expression of antibody or a fragment thereof in lactobacillus
AU2011296343B2 (en)	2010-08-30	2015-12-10	Pulmatrix Operating Company, Inc.	Dry powder formulations and methods for treating pulmonary diseases
EP2464346A1 (de)	2010-08-30	2012-06-20	Pulmatrix, Inc.	Behandlung zystischer fibrose mit calciumlactat, leukin und natriumchlorid in einem einatembaren trockenpulver
RU2017144619A (ru)	2010-09-29	2019-02-20	Пулмэтрикс, Инк.	Катионы одновалентных металлов сухих порошков для ингаляций
EP3470057B1 (de)	2010-09-29	2021-11-03	Pulmatrix Operating Company, Inc.	Kationische trockenpulver die magnesiumsalzen enthalten
US8623409B1 (en)	2010-10-20	2014-01-07	Tris Pharma Inc.	Clonidine formulation
US8287903B2 (en)	2011-02-15	2012-10-16	Tris Pharma Inc	Orally effective methylphenidate extended release powder and aqueous suspension product
US20130045958A1 (en)	2011-05-13	2013-02-21	Trimel Pharmaceuticals Corporation	Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en)	2011-05-13	2017-09-12	Acerus Pharmaceuticals Srl	Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AR086400A1 (es)	2011-05-13	2013-12-11	Trimel Pharmaceuticals Corp	Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
CN107596518B (zh)	2012-02-29	2021-04-23	普马特里克斯营业公司	可吸入干粉剂
CA2880456A1 (en)	2012-08-15	2014-02-20	Tris Pharma, Inc.	Methylphenidate extended release chewable tablet
US11744838B2 (en)	2013-03-15	2023-09-05	Acerus Biopharma Inc.	Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US10130120B2 (en) *	2013-03-15	2018-11-20	Altria Client Services Llc	Use of pectin or other anionic polymers in the stabilization and controlled release of nicotine in oral sensorial tobacco products or nicotine containing non-tobacco oral sensorial products
JP6473738B2 (ja)	2013-04-01	2019-02-20	パルマトリックス，インコーポレイテッド	チオトロピウム乾燥粉末
WO2015034678A2 (en)	2013-09-06	2015-03-12	Aptalis Pharmatech, Inc.	Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
DK3166563T3 (da) *	2014-07-08	2021-02-15	Fertin Pharma As	Oralt administrationssystem omfattende to rum
US11590228B1 (en)	2015-09-08	2023-02-28	Tris Pharma, Inc	Extended release amphetamine compositions
KR102587444B1 (ko)	2015-09-29	2023-10-11	킴벌리-클라크 월드와이드, 인크.	미생물총의 건강한 균형을 유지하기 위한 상승 조성물
US12447166B2 (en) *	2016-02-25	2025-10-21	Applied Biological Laboratories, Inc.	Compositions and methods for protecting against airborne pathogens and irritants
TWI728172B (zh)	2016-08-18	2021-05-21	美商愛戴爾製藥股份有限公司	治療嗜伊紅性食道炎之方法
CN106511374A (zh) *	2016-10-20	2017-03-22	安徽宇宁果胶股份有限公司	一种果胶妇科抑菌凝胶及其制备方法
MX389431B (es)	2017-02-28	2025-03-20	Kimberly Clark Co	Composicion sinergica para el mantenimiento del equilibrio saludable de la microflora.
US11590081B1 (en)	2017-09-24	2023-02-28	Tris Pharma, Inc	Extended release amphetamine tablets
US12458592B1 (en)	2017-09-24	2025-11-04	Tris Pharma, Inc.	Extended release amphetamine tablets
JP7519683B2 (ja) *	2018-10-18	2024-07-22	奥野製薬工業株式会社	アルミニウム合金の陽極酸化皮膜用封孔処理液
CN112022880A (zh) *	2020-09-16	2020-12-04	杭州倍荣生物科技有限公司	一种直肠黏膜损伤及创面修复溶胶液及其制作方法
US12310959B2 (en)	2019-12-09	2025-05-27	Nicoventures Trading Limited	Oral compositions with reduced water content
US12520867B2 (en)	2019-12-09	2026-01-13	Nicoventures Trading Limited	Buffered oral compositions
US12439949B2 (en)	2019-12-09	2025-10-14	Nicoventures Trading Limited	Oral compositions with reduced water activity
US12433321B2 (en)	2019-12-09	2025-10-07	Nicoventures Trading Limited	Oral composition with beet material
US20210169783A1 (en) *	2019-12-09	2021-06-10	Nicoventures Trading Limited	Oral products with controlled release
US11918689B1 (en)	2020-07-28	2024-03-05	Tris Pharma Inc	Liquid clonidine extended release composition
WO2022229833A1 (en) *	2021-04-26	2022-11-03	Politecnico Di Milano	Gel for the regeneration of mucosae
MX2023015529A (es)	2021-06-25	2024-03-05	Nicoventures Trading Ltd	Productos orales y metodo de fabricacion.

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2125212A (en) *	1938-05-03	1938-07-26	Vick Chemical Company	Therapeutic composition
US2730483A (en) *	1952-08-12	1956-01-10	Nepera Chemical Co Inc	Therapeutic compositions comprising neomycin, gramicidin and quaternary ammonium salt of thonzylamine
BE623427A (de) *	1961-10-10
JPS5885813A (ja) *	1981-11-17	1983-05-23	Toyo Jozo Co Ltd	吸収性良好な製剤
US4464378A (en) *	1981-04-28	1984-08-07	University Of Kentucky Research Foundation	Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4659696A (en) *	1982-04-30	1987-04-21	Takeda Chemical Industries, Ltd.	Pharmaceutical composition and its nasal or vaginal use
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
US4486423A (en) *	1983-04-21	1984-12-04	Janssen Pharmaceutica Inc.	Stable fentanyl composition
US4806341A (en) *	1985-02-25	1989-02-21	Rutgers, The State University Of New Jersey	Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
HU193780B (en) *	1985-06-21	1987-11-30	Richter Gedeon Vegyeszet	Process for producing 2-halogeno-6-methyl-ergol-9-ene derivatives and acid additional salts thereof
FR2588189B1 (fr) *	1985-10-03	1988-12-02	Merck Sharp & Dohme	Composition pharmaceutique de type a transition de phase liquide-gel
JPS62123112A (ja)	1985-11-22	1987-06-04	Sunstar Inc	軟膏基剤
DE3601132A1 (de)	1986-01-16	1987-07-23	Christian Bannert	Verfahren zur behandlung der schleimhaut
JPS62236862A (ja)	1986-04-09	1987-10-16	Nippon Kayaku Co Ltd	人工粘液
US4826683A (en) *	1987-01-09	1989-05-02	Bates Harry L	Decongestant
US5200180A (en) *	1987-06-26	1993-04-06	Christian Bannert	Pharmaceutical composition for the treatment of the human eye
DE3726797A1 (de) *	1987-08-12	1989-02-23	Bayer Ag	Arzneimittel fuer den bereich der mundhoehle
US4915948A (en)	1987-08-31	1990-04-10	Warner-Lambert Company	Tablets having improved bioadhesion to mucous membranes
US5457093A (en)	1987-09-18	1995-10-10	Ethicon, Inc.	Gel formulations containing growth factors
DE3827561C1 (de) *	1988-08-13	1989-12-28	Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5236714A (en) *	1988-11-01	1993-08-17	Alza Corporation	Abusable substance dosage form having reduced abuse potential
JP2911496B2 (ja) *	1989-09-11	1999-06-23	帝國製薬株式会社	生理活性ポリペプチド含有高吸収性経膣剤
US5707644A (en) *	1989-11-04	1998-01-13	Danbiosyst Uk Limited	Small particle compositions for intranasal drug delivery
US5397771A (en) *	1990-05-10	1995-03-14	Bechgaard International Research And Development A/S	Pharmaceutical preparation
US5346703A (en) *	1990-08-07	1994-09-13	Mediventures, Inc.	Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
JPH0597706A (ja) *	1991-04-09	1993-04-20	Chemex Block Drug Jv	アフタ性潰瘍および他の粘膜皮膚障害の処置方法
US5318780A (en) *	1991-10-30	1994-06-07	Mediventures Inc.	Medical uses of in situ formed gels
US5507277A (en) *	1993-01-29	1996-04-16	Aradigm Corporation	Lockout device for controlled release of drug from patient-activateddispenser
US5543434A (en) *	1994-02-25	1996-08-06	Weg; Stuart L.	Nasal administration of ketamine to manage pain
GB9406171D0 (en) *	1994-03-29	1994-05-18	Electrosols Ltd	Dispensing device
JP4137179B2 (ja) *	1994-03-30	2008-08-20	ジーエスディベロップメントエービー	生物付着性物質としての脂肪酸エステルの使用
JP3911290B2 (ja) *	1994-05-13	2007-05-09	アラダイムコーポレーション	エアゾールを含む麻酔用処方
GB9414966D0 (en) *	1994-07-26	1994-09-14	Danbiosyst Uk	Pharmaceutical compositions for the nasal administration of antiviral agents
US6667279B1 (en) *	1996-11-13	2003-12-23	Wallace, Inc.	Method and composition for forming water impermeable barrier
GB9707934D0 (en) *	1997-04-18	1997-06-04	Danbiosyst Uk	Improved delivery of drugs to mucosal surfaces
US6541021B1 (en) *	1999-03-18	2003-04-01	Durect Corporation	Devices and methods for pain management
CA2381860C (en) *	1999-08-26	2009-11-24	Takeda Chemical Industries, Ltd.	Matrix adhering to nasal mucosa
GB9924797D0 (en) *	1999-10-20	1999-12-22	West Pharm Serv Drug Res Ltd	Compound

1997
- 1997-04-18 GB GBGB9707934.7A patent/GB9707934D0/en active Pending
1998
- 1998-04-17 ZA ZA9803262A patent/ZA983262B/xx unknown
- 1998-04-20 GB GB9924123A patent/GB2340039B/en not_active Expired - Lifetime
- 1998-04-20 AT AT98917414T patent/ATE262925T1/de active
- 1998-04-20 PT PT98917414T patent/PT975367E/pt unknown
- 1998-04-20 JP JP54528598A patent/JP2001524094A/ja not_active Withdrawn
- 1998-04-20 US US09/402,976 patent/US6432440B1/en not_active Expired - Lifetime
- 1998-04-20 WO PCT/GB1998/001147 patent/WO1998047535A1/en not_active Ceased
- 1998-04-20 DK DK98917414T patent/DK0975367T3/da active
- 1998-04-20 NZ NZ337289A patent/NZ337289A/en not_active IP Right Cessation
- 1998-04-20 ES ES98917414T patent/ES2221706T3/es not_active Expired - Lifetime
- 1998-04-20 CA CA002282506A patent/CA2282506C/en not_active Expired - Lifetime
- 1998-04-20 EP EP98917414A patent/EP0975367B1/de not_active Expired - Lifetime
- 1998-04-20 DE DE69822805T patent/DE69822805T2/de not_active Expired - Lifetime
- 1998-04-20 DE DE122011000009C patent/DE122011000009I1/de active Pending
1999
- 1999-10-15 NO NO19995021A patent/NO321729B1/no not_active IP Right Cessation
2002
- 2002-07-15 US US10/196,590 patent/US20020197324A1/en not_active Abandoned
2006
- 2006-11-21 US US11/562,002 patent/US20070110677A1/en not_active Abandoned
- 2006-11-21 US US11/562,173 patent/US20070092535A1/en not_active Abandoned
2008
- 2008-10-03 JP JP2008257989A patent/JP4880657B2/ja not_active Expired - Lifetime
2010
- 2010-08-05 JP JP2010175973A patent/JP2010280695A/ja not_active Withdrawn
2011
- 2011-02-25 FR FR11C0006C patent/FR11C0006I1/fr active Active
- 2011-04-01 US US13/078,575 patent/US20110182857A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0975367B1 (de)	2004-03-31
JP2010280695A (ja)	2010-12-16
ES2221706T3 (es)	2005-01-01
GB9707934D0 (en)	1997-06-04
GB2340039B (en)	2002-02-06
AU7064798A (en)	1998-11-13
JP4880657B2 (ja)	2012-02-22
US20070092535A1 (en)	2007-04-26
US6432440B1 (en)	2002-08-13
ATE262925T1 (de)	2004-04-15
JP2001524094A (ja)	2001-11-27
DE69822805D1 (de)	2004-05-06
AU741847B2 (en)	2001-12-13
FR11C0006I1 (fr)	2011-04-08
JP2009079052A (ja)	2009-04-16
ZA983262B (en)	1999-10-18
GB2340039A (en)	2000-02-16
EP0975367A1 (de)	2000-02-02
DE122011000009I1 (de)	2011-06-16
CA2282506C (en)	2008-12-30
WO1998047535A1 (en)	1998-10-29
CA2282506A1 (en)	1998-10-29
PT975367E (pt)	2004-08-31
DE69822805T2 (de)	2005-02-17
US20110182857A1 (en)	2011-07-28
US20070110677A1 (en)	2007-05-17
NO995021L (no)	1999-10-15
DK0975367T3 (da)	2004-07-26
NZ337289A (en)	2001-06-29
NO995021D0 (no)	1999-10-15
US20020197324A1 (en)	2002-12-26
GB9924123D0 (en)	1999-12-15

Legal Events

Date	Code	Title	Description
2018-05-07	MK1K	Patent expired

Publication	Publication Date	Title
NO321729B1 (no)	2006-06-26	Forbedret system for administrasjon av medikamenter til slim-overflater
CN102079794B (zh)	2012-03-28	用于医药装置和药物制剂中的含有木葡聚糖的粘膜粘附性制剂
Anjali et al.	2020	Nasal in situ gel: novel approach for nasal drug delivery
CN101534794A (zh)	2009-09-16	用于递送眼科用药物的凝胶
CN101385697B (zh)	2012-10-03	氟比洛芬酯眼用纳米乳-原位凝胶制剂及其制备方法
Campaña-Seoane et al.	2014	Bioadhesive emulsions for control release of progesterone resistant to vaginal fluids clearance
EP1722759A2 (de)	2006-11-22	Chitosan-haltige lösung
More et al.	2015	A review on in-situ nasal gel drug delivery system
CN107362142B (zh)	2023-04-25	一种氟维司群脂质体注射液及其制备方法
Gupta et al.	2022	Understanding the routes of administration
CN102198087B (zh)	2013-01-23	一种不含防腐剂的眼用原位胶凝剂及其制备方法
JP2671381B2 (ja)	1997-10-29	点眼剤
CN106265664B (zh)	2019-05-07	一种复方卢帕他定的生物黏附性鼻用凝胶剂产品及制备方法
Kashid et al.	2016	Nasal gel as promising mucosal drug delivery
CN104721130B (zh)	2018-02-13	一种布林佐胺包合物眼用制剂及其制备方法
Nath et al.	2025	Nasal in situ gels: A novel approach for drug targeting to brain
RU2697411C2 (ru)	2019-08-14	Композиция для лечения болезни Паркинсона
Parbat et al.	2021	IN-SITU GEL FOR NASAL DRUG DELIVERY
Hussein et al.	2024	Formulation and Evaluation of Thermosensitive In situ Nasal Gel of Mirtazapine Loaded Aquasomes.
Malekar et al.	2015	In-situ nasal gel: a review
Saudagar et al.	2016	In-Situ Nasal Gel Drug Delivery: An Overview
BG65734B1 (bg)	2009-09-30	Течен мукоадхезивен фармацевтичен състав
CN104523575A (zh)	2015-04-22	一种盐酸羟苄唑眼用凝胶剂及其制备方法
JP5340667B2 (ja)	2013-11-13	眼科用薬剤
Panchal et al.	2017	Design and development of Betaxolol hydrochloride in situ hydrogel